“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

21 May 2019
Pharma

Visiongain has launched a new pharma report Global Urology Devices Market Forecast 2019-2029: Urinary Incontinence, Benign Prostatic Hyperplasia, Kidney Stone, Prostate Cancer.

In 2018, the urology devices market is estimated at $6.9 billion. The market is expected to grow at a CAGR of 6.1% from 2018 to 2029. Products included in the urology devices market include catheters, slings, brachytherapy, radiation therapy devices, accessories and others. The urinary incontinence market dominated the market in 2018 and accounted for 33.8% of the urology devices market.

The lead analyst of the report commented "The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs. Other factors contributing to the growth of the market are preference for minimally invasive procedures and rising incidence of obesity. The market has certain restraining factors such as high cost of devices and social stigma associated with the disease."

Leading companies featured in the report include C.R. Bard, Coloplast, Endo Pharmaceuticals, Boston Scientific Corporation, Healthtronics, Lumenis, Medtronic, Siemens Healthcare, Urologix and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever